A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

September 13, 2024

Study Completion Date

September 13, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

ADCT-901

Intravenous infusion

Trial Locations (13)

28040

(START) Madrid - Hospital Universitario Fundación Jiménez Díaz Location, Madrid

28041

Universidad Complutense de Madrid - Hospital Universitario 12 de Octubre, Madrid

30322

Emory University, Winship Cancer Institute, Atlanta

44106

University Hospitals of Cleveland Medical Center (UHCMC), Cleveland

60611

Northwestern University, Chicago

73104

Sarah Cannon at University of Oklahoma Health Sciences Center, Oklahoma City

78229

NEXT Oncology, San Antonio

80218

Sarah Cannon at HealthONE, Denver

06520

Yale Cancer Center, New Haven

08908

Institut Catala D'oncologia (ICO) - Hospital Duran I Reynals Location, Badalona

08035

Hospital Universitari Vall D'hebron - Vall D'hebron Institut D'oncologia (VHIO), Barcelona

W12 0HS

Imperial College Healthcare NHS Trust - St Mary's Hospital, London

W1G 6AD

Sarah Cannon Research Institute (SCRI) - London (SCRI-UK), London

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY